Enliven Therapeutics director sells 10,000 shares

Enliven Therapeutics, Inc. director Lori Anne Kunkel reported selling a total of 10,000 shares of common stock in open-market transactions on July 6, 2026.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. director Lori Anne Kunkel reported selling a total of 10,000 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices of $50.8442 and $49.9834 per share.

According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the sales were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 2 txns

Insider Kunkel Lori Anne

Role Director

Sold 10,000 shs ($505K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,111	$49.9834	$205K
Sale	Common Stock	5,889	$50.8442	$299K

Holdings After Transaction: Common Stock — 41,884 shares (Direct)

Footnotes (3)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
2. F2. This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold (first transaction): 5,889 shares Price per share (first transaction): $50.8442 per share Shares sold (second transaction): 4,111 shares +2 more

5 metrics

Shares sold (first transaction) 5,889 shares Open-market sale of common stock on July 6, 2026

Price per share (first transaction) $50.8442 per share Weighted average sale price for 5,889 shares

Shares sold (second transaction) 4,111 shares Open-market sale of common stock on July 6, 2026

Price per share (second transaction) $49.9834 per share Weighted average sale price for 4,111 shares

Total shares sold 10,000 shares Aggregate of two open-market sales reported in Form 4

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enliven Therapeutics (ELVN) report?

Enliven Therapeutics reported that director Lori Anne Kunkel sold 10,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at weighted average prices around $50 per share, as disclosed in a Form 4 filing.

At what prices did Lori Anne Kunkel sell Enliven Therapeutics (ELVN) shares?

Lori Anne Kunkel sold 5,889 shares at a weighted average price of $50.8442 and 4,111 shares at $49.9834 per share. Each transaction was executed in multiple trades within specified price ranges detailed in the Form 4 footnotes.

How many Enliven Therapeutics (ELVN) shares did the director sell in total?

The director sold a total of 10,000 Enliven Therapeutics common shares, split between two open-market sale transactions. One covered 5,889 shares and the other 4,111 shares, both executed on July 6, 2026 under a pre-arranged trading plan.

Were the Enliven Therapeutics (ELVN) insider sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Lori Anne Kunkel on March 6, 2026. Such plans schedule trades in advance, reducing the significance of the exact sale timing for market signaling.

What type of transaction code was used in the Enliven Therapeutics (ELVN) Form 4?

Both transactions were coded “S,” indicating open-market or private sale of non-derivative common stock. This code confirms the reported activity was outright share dispositions, not option exercises, gifts, or tax-withholding events.

Did the Enliven Therapeutics (ELVN) Form 4 disclose trade price ranges?

Yes. One transaction’s trades occurred between $49.40 and $50.395 per share, and the other between $50.4306 and $51.3752. The reported prices are weighted averages, and the insider undertook to provide full trade breakdowns upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 05:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Lori Anne

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		4,111	D	$49.9834(2)	47,773	D
Common Stock	07/06/2026		S(1)		5,889	D	$50.8442(3)	41,884	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026

2. This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Ben Hohl, by power of attorney	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)